ClaireLewis at 05:47, 21 April 2021

2021-04-21T05:47:13Z

← Revisión anterior		Revisión del 05:47 21 abr 2021
Línea 1:		Línea 1:
	==Administration==		==Administration==
	*Type:		*Type:
	*Dosage Forms:		*Dosage Forms: suspension, tablet
	*Routes of Administration:		*Routes of Administration: PO
	*Common Trade Names: Carafate		*Common Trade Names: Carafate

	==Adult Dosing==		==Adult Dosing==
			*[[Duodenal ulcer]]
			**Active ulcer treatment: 1g PO 4 times daily x 4-8 weeks
			**Maintenance therapy: 1g twice daily

	==Pediatric Dosing==		==Pediatric Dosing==
			*[[Peptic ulcer disease]]: 40-80 mg/kg/day divided q6 hours, maximum 1000mg/dose
			*Esophagitis
			**3 months-6 years of age: 500mg PO 4 times daily
			**>6 years: 1000mg/dose four times daily

	==Special Populations==		==Special Populations==
	===[[Drug pregnancy categories\|Pregnancy Rating]]===		===[[Drug pregnancy categories\|Pregnancy Rating]]===
	*		*B: Acceptable for use in pregnancy

	===Lactation risk===		===Lactation risk===
	*		*Use considered acceptable

	===Renal Dosing===		===Renal Dosing===
	*~~Adult:~~		*Use caution in chronic renal failure or dialysis due to absorption of aluminum salts
	*Pediatric:

	===Hepatic Dosing===		===Hepatic Dosing===
	*~~Adult:~~		*No adjustment
	*Pediatric:

	==Contraindications==		==Contraindications==
Línea 31:		Línea 34:
	==Adverse Reactions==		==Adverse Reactions==
	===Serious===		===Serious===
			*Anaphylaxis
			*Bronchospasm, laryngeal/pharyngeal/pulmonary edema

	===Common===		===Common===
			*Constipation

	==Pharmacology==		==Pharmacology==
			Acts locally in GI tract, minimally absorbed
	*Half-life:		*Half-life:
	*Metabolism:		*Metabolism: none
	*Excretion:		*Excretion:

	==Mechanism of Action==		==Mechanism of Action==
			*Binds to form complex with positively charged proteins in exudates, forming a viscous paste-like adhesive substance, which then selectively forms a protective coating that protects gastric lining against peptic acid, pepsin, and bile salts

	==Comments==		==Comments==
Línea 48:		Línea 53:

	==See Also==		==See Also==
			*[[peptic ulcer disease]]

	==References==		==References==
	<references/>		<references/>
			Uptodate

	[[Category:Pharmacology]]		[[Category:Pharmacology]]

Elcatracho: Created page with "==Administration== Type: Dosage Forms: Routes of Administration: Common Trade Names: Carafate ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== ===Drug..."

2021-03-05T23:06:15Z

Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: Carafate ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== ===Drug..."

Página nueva

==Administration==
*Type:
*Dosage Forms:
*Routes of Administration:
*Common Trade Names: Carafate

==Adult Dosing==

==Pediatric Dosing==

==Special Populations==
===[[Drug pregnancy categories|Pregnancy Rating]]===
*

===Lactation risk===
*

===Renal Dosing===
*Adult:
*Pediatric:

===Hepatic Dosing===
*Adult:
*Pediatric:

==Contraindications==
*Allergy to class/drug

==Adverse Reactions==
===Serious===

===Common===

==Pharmacology==
*Half-life:
*Metabolism:
*Excretion:

==Mechanism of Action==

==Comments==

==See Also==

==References==
<references/>

[[Category:Pharmacology]]

Sucralfate - Revision history

ClaireLewis at 05:47, 21 April 2021

Elcatracho: Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: Carafate ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== ===Drug..."

Elcatracho: Created page with "==Administration== Type: Dosage Forms: Routes of Administration: Common Trade Names: Carafate ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== ===Drug..."